What question did this study set out to answer?

To compare progression-free and overall survival between melphalan 140 mg/m² and melphalan 200 mg/m² conditioning regimens in multiple myeloma patients receiving bortezomib-based induction before autologous stem cell transplantation.

March 28, 2021Journal of Health Sciences and MedicineOpen Access

Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents

View Full Paper

Ask AI

Bookmark

Authors

BUBahar Uncu Ulu MBMehmet Bakırtaş TYTuğçe Nur Yiğenoğlu

Discussion

Member takes

Overview

Retrospective study finds comparable survival between reduced and standard melphalan conditioning in multiple myeloma, suggesting lower doses may be viable after modern induction therapy.

Key Points

To compare progression-free and overall survival between melphalan 140 mg/m² and melphalan 200 mg/m² conditioning regimens in multiple myeloma patients receiving bortezomib-based induction before autologous stem cell transplantation.
Retrospective single-center analysis of 84 multiple myeloma patients who underwent autologous stem cell transplantation between 2010 and 2018.
Patients received bortezomib-containing combination induction followed by conditioning with either melphalan 140 mg/m² (MEL 140) or melphalan 200 mg/m² (MEL 200).
Progression-free survival was 9 months (95% CI, 2.2–15.8) in the MEL 140 group versus 13 months (95% CI, 10.5–15.5) in the MEL 200 group (p = 0.6).
Overall survival was 30 months (95% CI, 9.5–50.4) for MEL 140 compared to 34 months (95% CI, 6.9–61.0) for MEL 200 (p = 0.7).
Engraftment duration and transplant-related mortality rates were similar between the two conditioning cohorts.

Cite This Study

Ulu et al. (2021) studied this question.

synapsesocial.com/papers/6aa4a3d6997531f8901426f5 https://doi.org/10.32322/jhsm.868279

View Full Paper

Ask AI

Bookmark

March 28, 2021Journal of Health Sciences and MedicineOpen Access

Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents

View Full Paper

Ask AI

Bookmark

Authors

BUBahar Uncu Ulu MBMehmet Bakırtaş TYTuğçe Nur Yiğenoğlu

Discussion

Member takes

Overview

Retrospective study finds comparable survival between reduced and standard melphalan conditioning in multiple myeloma, suggesting lower doses may be viable after modern induction therapy.

Key Points

To compare progression-free and overall survival between melphalan 140 mg/m² and melphalan 200 mg/m² conditioning regimens in multiple myeloma patients receiving bortezomib-based induction before autologous stem cell transplantation.
Retrospective single-center analysis of 84 multiple myeloma patients who underwent autologous stem cell transplantation between 2010 and 2018.
Patients received bortezomib-containing combination induction followed by conditioning with either melphalan 140 mg/m² (MEL 140) or melphalan 200 mg/m² (MEL 200).
Progression-free survival was 9 months (95% CI, 2.2–15.8) in the MEL 140 group versus 13 months (95% CI, 10.5–15.5) in the MEL 200 group (p = 0.6).
Overall survival was 30 months (95% CI, 9.5–50.4) for MEL 140 compared to 34 months (95% CI, 6.9–61.0) for MEL 200 (p = 0.7).
Engraftment duration and transplant-related mortality rates were similar between the two conditioning cohorts.

Cite This Study

Ulu et al. (2021) studied this question.

synapsesocial.com/papers/6aa4a3d6997531f8901426f5 https://doi.org/10.32322/jhsm.868279

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark